X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PROCTER & GAMBLE HEALTH - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PROCTER & GAMBLE HEALTH NOVARTIS/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 462.8 51.4 901.2% View Chart
P/BV x 26.8 4.6 577.6% View Chart
Dividend Yield % 1.7 10.2 16.7%  

Financials

 NOVARTIS   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    NOVARTIS
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
NOVARTIS/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs7583,549 21.4%   
Low Rs5791,301 44.5%   
Sales per share (Unadj.) Rs228.4511.4 44.7%  
Earnings per share (Unadj.) Rs31.761.3 51.8%  
Cash flow per share (Unadj.) Rs32.874.0 44.3%  
Dividends per share (Unadj.) Rs10.00440.00 2.3%  
Dividend yield (eoy) %1.518.1 8.2%  
Book value per share (Unadj.) Rs297.1927.8 32.0%  
Shares outstanding (eoy) m24.6916.60 148.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.7 61.7%   
Avg P/E ratio x21.139.6 53.2%  
P/CF ratio (eoy) x20.432.8 62.3%  
Price / Book Value ratio x2.22.6 86.1%  
Dividend payout %31.5717.9 4.4%   
Avg Mkt Cap Rs m16,50540,257 41.0%   
No. of employees `0000.71.1 58.9%   
Total wages/salary Rs m1,4451,313 110.1%   
Avg. sales/employee Rs Th8,441.37,486.7 112.8%   
Avg. wages/employee Rs Th2,163.61,157.6 186.9%   
Avg. net profit/employee Rs Th1,173.1897.2 130.7%   
INCOME DATA
Net Sales Rs m5,6398,490 66.4%  
Other income Rs m1,718244 704.5%   
Total revenues Rs m7,3578,734 84.2%   
Gross profit Rs m-631,482 -4.2%  
Depreciation Rs m25211 12.0%   
Interest Rs m550-   
Profit before tax Rs m1,5751,514 104.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m792563 140.7%   
Profit after tax Rs m7841,017 77.0%  
Gross profit margin %-1.117.5 -6.4%  
Effective tax rate %50.337.1 135.3%   
Net profit margin %13.912.0 116.0%  
BALANCE SHEET DATA
Current assets Rs m9,52215,343 62.1%   
Current liabilities Rs m3,2961,960 168.1%   
Net working cap to sales %110.4157.6 70.0%  
Current ratio x2.97.8 36.9%  
Inventory Days Days3749 75.1%  
Debtors Days Days2828 99.9%  
Net fixed assets Rs m461,209 3.8%   
Share capital Rs m123166 74.3%   
"Free" reserves Rs m7,21315,235 47.3%   
Net worth Rs m7,33615,401 47.6%   
Long term debt Rs m00-   
Total assets Rs m11,10517,595 63.1%  
Interest coverage x29.5NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 105.2%   
Return on assets %7.65.8 130.6%  
Return on equity %10.76.6 161.7%  
Return on capital %22.210.3 216.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m611,636 3.7%   
Fx outflow Rs m3,6304,368 83.1%   
Net fx Rs m-3,570-2,732 130.7%   
CASH FLOW
From Operations Rs m1,610-1,304 -123.5%  
From Investments Rs m68712,697 5.4%  
From Financial Activity Rs m-2,677-301 890.7%  
Net Cashflow Rs m-38011,093 -3.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 2.0 18.2 11.0%  
FIIs % 1.6 1.0 160.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 29.1 73.9%  
Shareholders   41,647 28,591 145.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling, Passenger Vehicles Sales Data, and Top Cues in Focus Today(Pre-Open)

India share markets witnessed selling pressure yesterday and ended their session deep in the red. At the closing bell yesterday, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 21, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS